Clinical Trial Update: Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated neratinib with and without temsirolimus in patients with HER2-activating mutations in non-small cell lung cancer; the study completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mutant Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Temsirolimus (temsirolimus)
• neratinib (neratinib)

Snippet

Sponsor: Puma Biotechnology, Inc. | Conditions: HER2-mutant Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-09-11